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QT prolongationThe aim of this work was to evaluate the cardiac risk for etamicastat, a peripheral reversible dopamine-β-
hydroxylase inhibitor. Etamicastat blocked the hERG current amplitude with an IC50 value of 44 μg/ml.
Etamicastat had no substantial effects on arterial blood pressure, heart rate and the PR interval in male
Cynomolgus monkeys when administered orally up to 90 mg/kg. Administered orally at 15 and
45 mg/kg/day in female and male Cynomolgus monkey for 91 days, etamicastat had no effect on heart
rate and the waveform or intervals of the electrocardiogram. At the highest dose level of 45 mg/kg, mean
plasma concentrations of etamicastat ranged from 1875 to 3145 ng/ml on Day 1 and Day 91 of treatment,
respectively. The effect of age on the tolerability and pharmacokinetics of etamicastat in elderly
(≥65 years) and young adult (18–45 years) subjects showed that supine systolic (SBP) and diastolic
(DBP) blood pressure, ECG heart rate, PR interval, QRS duration and QTcF interval were not affected follow-
ing once-daily administration of 100mg/day etamicastat for 7 days. In hypertensive patients the decrease of
blood pressure tended to bemore important in subjects who had received etamicastat (50, 100 and 200mg)
than in subjects who had received placebo. No clinically signiﬁcant out-of-range values in vital signs or ECG
parameters, ECG heart rate, PR interval, QRS duration and QTcF interval were observed in hypertensive
subjects following once-daily administration of etamicastat for 10 days. In conclusion, etamicastat is not
likely to prolong the QT interval at therapeutic doses.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is anopen access article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Interest in the development of inhibitors of dopamine β-hydroxylase
(DβH; EC 1.14.17.1; dopamine β-monooxygenase) is centered on the
hypothesis that inhibition of this enzyme may provide signiﬁcant
clinical improvements in patients suffering from cardiovascular
disorders such as hypertension or congestive heart failure [1–8].
The rationale for the use of DβH inhibitors is based on their capacity
to inhibit the biosynthesis of noradrenaline, which is achieved via
enzymatic hydroxylation of dopamine [9–13].development, BIAL— Portela &
: +351 229866100; fax: +351
ilva).
land Ltd. This is an open access articleSeveral DβH inhibitors have been reported [4–6], but none achieved
marketing approval due toweakpotency, poor DBHselectivity [14] and/
or signiﬁcant adverse effects [15]. Nepicastat, (Fig. 1) a 5-substituted
imidazole-2-thione derivative, is a highly potent DβH inhibitor that, in
beagle dogs, produced a dose-dependent noradrenaline reduction and
dopamine increase in the renal artery, heart left ventricle and cerebral
cortex [7]. These data indicate that nepicastat crosses the blood–brain
barrier (BBB) causing central as well as peripheral effects, a situation
that could lead to undesired and potentially serious CNS adverse effects.
Etamicastat, also known as BIA 5–453, (Fig. 1) is a reversible DβH inhibi-
tor that prevents the conversion of dopamine to noradrenaline in sympa-
thetically innervated tissues and reduces sympathetic nervous system
activity [1,2,14]. As a result of its reduced ability to cross the blood–
brain barrier [1], etamicastat acts preferentially in the periphery and is
currently being developed for the treatment of cardiovascular diseases.under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Structural formulae of etamicastat and nepicastat.
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dopamine andnoradrenaline tissue levels in the brain [1],which is unique
among the DβH inhibitors previously tested for the treatment of cardio-
vascular disorders [3,8,14].
As previously observed with other DβH inhibitors that are endowed
with potent antihypertensive effects in the spontaneously hypertensive
rat [6], etamicastat showed to reduce both systolic (SBP) and diastolic
(DBP) blood pressure, alone or in combinationwith other antihyperten-
sive drugs, and to decrease the urinary excretion of noradrenaline in
spontaneously hypertensive rats with no change in heart rate [16–19].
Recently, etamicastat demonstrated blood pressure lowering effects in
hypertensive patients [20]. In healthy subjects, etamicastatwaswell tol-
erated and showed approximate linear pharmacokinetics following sin-
gle oral doses [21] and multiple once-daily oral doses [22], with no
signiﬁcant differences being observed in elderly versus young healthy
subjects [23].
The aimof the presentworkwas to evaluate the effects of etamicastat
for cardiac risk both in vitro, testing on the hERG potassium channel of
human embryonic kidney (HEK293) cells, and in vivo in the Cynomolgus
monkeymonitored by telemetry (up to 90mg/kg etamicastat). This eval-
uation was complemented in male and female Cynomolgus monkey
dosed daily with etamicastat (up to 45 mg/kg/day) for at least 91 days,
and in three clinical studies in human healthy volunteers receiving single
doses of etamicastat (up to 1200mg), young and elderly healthy subjects
receiving etamicastat (100mg/day) for 7 days, andhypertensive patients
administered once-daily with etamicastat (up to 200 mg) for up to
10 days.
2. Methods
2.1. In vitro studies
2.1.1. DβH activity
DβH activity was measured by a modiﬁcation of the method of
Nagatsu and Udenfriend [24], which is based on the enzymatic hydrox-
ylation of tyramine into octopamine, in SK-N-SH cell homogenates. SK-
N-SH cells (ATCC HTB-11) obtained from LGC Standards (Tedington,
UK) were cultured in Eagle's minimum essential medium supplement-
ed with 25 mM Hepes, 100 U/ml penicillin G, 0.25 μg/ml amphotericin
B, 100 μg/ml streptomycin and 10% Gibco® fetal bovine serum. Cells
were grown in T162 cm ﬂasks (Corning, NY) in a humidiﬁed atmo-
sphere of 5% CO2–95% air at 37 °C. For the preparation of homogenates,
fetal bovine serumwas removed from cell medium 4 h prior to homog-
enate preparation. At the appropriate timemedia was removed and cell
monolayers were washed with 50 mM Tris–HCl pH 7.4. Cells were sub-
sequently scrapped off the ﬂasks and were resuspended in 50 mM Tris
pH 7.4. Cell suspensions were homogenized with SilentCrusher M
(Heidolph) for a short stroke and homogenates were aliquoted and
were stored frozen at−80 °C. Total protein in cell homogenateswas de-
termined with the BioRad Protein Assay (BioRad) using a standard
curve of BSA (50–250 μg/ml). The octopamine formed is subsequentlyoxidized to p-hydroxybenzaldehyde and measured by spectrophotom-
etry. Experimental assay conditions for the cellular homogenates were
previously optimized by evaluating time and protein dependency of
the enzymatic assay. In brief, reaction mixture (total volume 500 μl)
contained: cellular homogenate (75 μg total protein) sodium acetate
pH 5.0 (200mM), NEM (30 mM), CuSO4 (5 μM), catalase aqueous solu-
tion (0.5 mg/ml), pargyline–HCl (1 mM), sodium fumarate (10 mM),
ascorbic acid (10 mM), inhibitor or vehicle and tyramine (25 mM).
After a 10min pre-incubation period at 37 °C, the reaction was initiated
by the addition of tyramine. Reactionwas carried out for 45min at 37 °C
before termination with 50 μl PCA (2 M). Samples were centrifuged for
3 min at 16,100 g and supernatants were transferred to SPE cartridges
ISOLUTE SCX-3 (100 mg, 1 ml) previously equilibrated with MilliQ
water. Columns were centrifuged at 150 g for 2 min. Eluate was
discarded and matrix was washed with 1 ml of MilliQ water after
which octopamine was eluted with 2 × 0.25 ml ammonium hydroxide
(4 M). The oxidation of octopamine to p-hydroxybenzaldehyde was
carried out for 6 min with 100 μl sodium periodate (2%) and was
stopped with 100 μl sodium metabisulﬁte (10%). Absorbance was
measured at 330 nm on a Spectramax microplate reader (Molecular
Devices, Sunnyvale, CA). Under the experimental conditions de-
scribed in above, cellular homogenates were incubated with various
concentrations (1, 3, 10, 30, 100, 300, 1000, 3000 nM) of either
etamicastat, or nepicastat.
2.1.2. hERG K+ channel
The whole-cell patch-clamp technique was used to investigate the
effects of etamicastat and nepicastat on hERGpotassiumchannels stably
expressed in stably transfected human embryonic kidney (HEK 293)
cells. Both compounds were tested at concentrations of 0.3 to
35.0 μg/ml in order to determine their effects on the hERG mediated
current. All solutions applied to cells including the pipette solutionwere
maintained at room temperature (19–30 °C). A vehicle group (water
for injection 1% used as solvent for etamicastat and nepicastat) was
included in the study for comparison, and E-4031 (1 μM), which selec-
tively blocks the rapid delayed rectiﬁer potassium current IKr, was used
as reference substance.
HEK 293 cells stably expressing the hERG channel were incubated at
37 °C in a humidiﬁed atmosphere with 5% CO2. For electrophysiological
measurements, HEK 293 cells were seeded onto 35 mm sterile culture
dishes containing 2ml culturemediumwithout antibiotics. Tetracycline
was added to induce channel expression. Because responses in distant
cells are not adequately voltage clamped and because of uncertainties
about the extent of coupling [25], cells were cultivated at a density
that enabled single cells (without visible connections to neighboring
cells) to be measured. The cells were continuously maintained in and
passaged in sterile culture ﬂasks containing a 1:1 mixture of Dulbecco's
modiﬁed eagle medium and nutrient mixture F-12 (D-MEM/F-12 1×,
liquid, with GlutaMax I, Gibco-BRL) supplemented with 9% fetal bovine
serum (Gibco-BRL) and 0.9% penicillin/streptomycin solution (Gibco-
BRL). The complete medium as indicated above was supplemented
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(Invitrogen). The ﬁnal bath solution had the following composition (in
mM): NaCl 137, KCl 4, CaCl2 1.8, MgCl2 1, HEPES 10, D-Glucose 10, pH
(NaOH) 7.4. The pipette solution had the following composition (in
mM): KCl 130, MgCl2 1, Mg-ATP 5, HEPES 10, EGTA 5, pH (KOH) 7.2.
The 35 mm culture dishes upon which cells were seeded at a density
allowing single cells to be recorded were placed on the dish holder of
the microscope and continuously perfused (approximately 1 ml/min)
with the bath solution. All solutions applied to cells including the pi-
pette solution were maintained at room temperature (19–30 °C). After
formation of a Gigaohm seal between the patch electrodes and individ-
ual hERG stably transfected HEK 293 cells (pipette resistance range:
2.0 MW–7.0 MW; seal resistance range: N1 GW), the cell membrane
across the pipette tip was ruptured to assure electrical access to the
cell interior (whole-cell patch-conﬁguration). As soon as a stable seal
was established, hERG outward tail currents were measured upon de-
polarization of the cellmembrane to+20mV for 2 s (activation of chan-
nels) from a holding potential of −80 mV and upon subsequent
repolarization to −40 mV for 3 s. This voltage protocol was run at
least 10 times at intervals of 10 s. If current density was judged to be
too low for measurement, another cell was recorded. Once control re-
cordings had been accomplished, cells were continuously perfused
with a bath solution containing etamicastat at 3, 10, 30 and 100 μM.
During wash-in of the test item, the voltage protocol indicated above
was run continuously again at 10 s intervals until the steady-state
level of block was reached. Complete cumulative concentration-
response analysis was accomplished per cell and the IC50 value was
calculated. After measurement of the control period, concentrations of
etamicastat were applied to the perfusion bath. During wash-in of
etamicastat, the voltage protocol was run until the steady-state level
of channel inhibitionwas reached. Values (in pA/nA) of the peak ampli-
tudes of outward tail currents were generated for each voltage step. The
recorded current amplitudes at the steady-state level of current inhibi-
tion were compared to those from control conditions measured in the
pre-treatment phase of the same cell. The amount of current block
was calculated as percentage of control. To determine whether any
observed current inhibition was due to etamicastat interaction
with the hERG channel or due to current rundown, these residual
currents were compared to those measured in vehicle treated cells.
Data from 3 individual cells were collected and the corresponding
mean values and standard errors calculated. For the validation of
the test system, the selective IKr blocker E-4031 was evaluated at
100 nM in 3 cells.2.2. In vivo studies
2.2.1. Cynomolgus primates
For cardiac and pharmacokinetic assessments, male and female
Cynomolgus monkeys, with bodyweight ranging from 1.8 to 2.7 kg
(females) and 2.2–3.1 kg (males), were obtained from Bioculture
Mauritius Ltd. (Senneville, Riviere des Anguilles, Mauritius) or Guangxi
Grand forest Scientiﬁc Primate Company (Beijing, China). The animals
were housed in group cages. Each cage contained all animals of the
same sex and treatment group. The animal house was maintained
under a 12-h ﬂuorescent light/12-h dark cycle at a controlled ambi-
ent temperature of 20–24 °C and relative humidity ranged from 40
to 70%. Animal diet consisted of pelleted standard Teklad diet 2055
and 2055C monkey diet (150 g/day/animal) and a fresh piece of
fruit four times a week. During the treatment period, the diet was of-
fered approximately 1 h after completion of dosing. Any remaining
diet was withdrawn early on the following day. All animal interven-
tions were performed in accordance with the European Directive
number 86/609, and the rules of the “Guide for the Care and Use of
Laboratory Animals”, 7th edition, 1996, Institute for Laboratory Ani-
mal Research (ILAR), Washington, DC.2.2.1.1. Telemetry monitored evaluations in Cynomolgus primates. The
effects of etamicastat (15, 45 and 90 mg/kg) on arterial blood pressure,
heart rate and themain parameters of the electrocardiogramwere eval-
uated following oral (p.o. capsule) administration in the consciousmale
Cynomolgus primate monitored by telemetry. The doses of etamicastat
were based on the results from a maximum tolerated dose (MTD)
study in Cynomolgus monkeys in which the MTD was established as
120 mg/kg/day (BIAL data on ﬁle). There was 1 treatment group of 4
primates following a 4×4 Latin-square design. Therewas awashout pe-
riod of 1week between each treatment. Animals were dosed at approx-
imately the same time each day. Venous blood samples (approximately
1 ml) for determination of etamicastat in plasma were taken prior to
dosing and at 2 and 4 h after the start of dose administration, or as
close as was reasonably practicable to these time points.
Four male Cynomolgus primates were surgically implanted with
telemetry transducers, type TL11M2-D70-PCT (Data Sciences Interna-
tional), for the measurement of arterial blood pressure and lead II elec-
trocardiogram (ECG). Brieﬂy, using sterile techniques and with the
animals anaesthetized with isoﬂuorane, the implant body was placed
intraperitoneally in the lower quarters of the abdominal cavity and
the blood pressure catheter introduced into the femoral artery with
the tip estimated to be in the terminal abdominal aorta. The ECG elec-
trodes were tunneled subcutaneously and ﬁxed in the thorax to give a
lead II ECG waveform morphology. Approximately 3 weeks later, i.e.
after a recovery period during which visual inspection of waveform
morphology of arterial blood pressure and of the ECG was performed
at times to conﬁrm suitability of the animals, a telemetry receiver was
positioned nearby each animal's home cage to record mean blood pres-
sure (MBP), SBP and DBP and heart rate (HR), which was derived from
pulse blood pressure. The PR and the QT intervals (ms) were also mea-
sured and the QTc interval was calculated according to Fridericia's for-
mula [QTcF = QT (ms) / 3√[60/HR(bpm)], and to individual animal
speciﬁc correction formula [QTcQ = QT (ms) + #(500-RR)]. Arterial
blood pressure, heart rate and lead II ECG variables in all groups were
extracted at −0.5, 1, 2, 4, 6, 8, 10, 14, 18 and 22 h post-dose, where
time 0 is the time at the end of dosing. Etamicastat was examined at 3
ascending single doses, i.e. 15, 45 and 90 mg/kg, administered p.o. (as
powder using gelatine capsules). Each animal received the vehicle
(empty capsule), then etamicastat, with a washout period of at least
5 days between each treatment. The animalswere offered food between
approximately 2 h post-dosing, on completion of the blood sampling.
Approximately 1 ml of venous blood was collected from a jugular vein
into lithium-heparinized glass vacuum tubes before and 2 and 4 h
after the administration of etamicastat or vehicle; the tubes were stored
in ice until centrifugation (approximately 1500 g at 4 °C for 15min) and
until required for analysis.
2.2.1.2. Cardiac evaluation after repeated oral administration in Cynomolgus
primates. Four animals of each sex were dosed daily by oral capsule at 0,
15 and 45 mg/kg/day for at least 91 days. On each day of treatment, the
animals were housed individually immediately prior to and after dosing
to allow detection of any treatment-related clinical signs. Thereafter,
the animals were released into group cages to allow interaction within
the dose group and sex. Animals were dosed orally by gastric gavage
and individual doseswere adjustedweekly according to themost recent-
ly recorded bodyweight. ECGs were recorded for all animals before the
start of treatment and again before dosing and 1 h after dosing on one
day during Week 1 and Week 13 of the study. Electrocardiograms were
obtained using Einthoven (I, II and III) and Goldberger (aVR, aVL, aVF)
leads. The heart rate, P wave duration and amplitude, P–Q interval, QRS
interval and Q–T intervals were measured manually using a representa-
tive section of the electrocardiogram from lead II, on the basis of an aver-
age of at least 10 consecutive complexes data.
Blood samples for the determination of plasma concentrations of
etamicastat were taken, by direct vein puncture, into lithium-heparin
tubes at pre-dose and then at 1, 2, 4, 8, 12 and 24 h after dosing. After
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Fig. 2. Inhibition curve for inhibition of dopamine-β-hydroxylase activity by etamicastat
and nepicatsat. Values are means ± SEM (n= 6).
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10 min at 4 °C. The resulting plasma was then separated into 2 aliquots
of 250 μl and stored at−80 °C until required for analysis.
2.2.2. Human subjects
The healthy status of human volunteerswas determined by an inter-
view, medical history, physical examination, vital signs, 12-lead ECG,
and results of clinical laboratory safety tests (including hematology,
plasma biochemistry), urinalysis, drugs of abuse screen, and HIV and
hepatitis B and C serology considered clinically acceptable at screening
and admission. At admission to the unit, the medical history and phys-
ical examination were updated. Etamicastat was administered in the
morning, with 250 ml of water, after at least 8 h of fasting. The doses
were obtained as combinations of etamicastat 1 mg, 10 mg and 50 mg
capsules and placebo capsules identical in appearance manufactured
by BIAL (S. Mamede do Coronado, Portugal). Healthy subjects partici-
pating in the single ascending dose study were requested to abstain
from consuming grapefruit or other citrus (e.g. orange) or their juice,
and alcohol- or xanthine-containing beverages or foods until 120 h
after the last dose. Hypertensive patients participating in the hyperten-
sion study were required to abstain from strenuous physical activity,
smoking, consumption of grapefruit or other citrus fruit (e.g. orange)
or of their juice, alcohol and beverages containing xanthine derivatives
(i.e. no coffee, tea, chocolate or Coca-Cola like drinks) from2days before
the ﬁrst dose until 72 h after the last dose. Concomitant medications
were not permitted throughout the study, unless required for treatment
of adverse events (AEs). Blood samples (3 ml) for the determination of
plasma concentrations of etamicastat and itsmetabolite BIA 5–961were
collected in lithium-heparin Vacuette® (Greiner Bio-One) tubes by
means of an indwelling catheter or venipuncture at the following
time points: pre dose, and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48,
72, 96, and 120 h post dose in the young and elderly study, or at pre-
dose and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 48 and 72 h post last dose
(Day 10) in the hypertensive patient study. After collection, blood sam-
ples were placed on ice and within 60 min after collection, the blood
samples were centrifuged at approximately 1500 g and at 4 °C during
10 min. For the assay of etamicastat and metabolites, 4 aliquots of
250 μl each of the resulting plasma were withdrawn and placed
into 2-ml cryotubes which were labeled, frozen and stored at
b−70 °C until analysis. Safety was evaluated from reported AEs,
physical examination, vital signs, digital 12-lead ECG, and clinical
laboratory test results.
2.2.2.1. Cardiac evaluation after single ascending administration in young
healthy humans. This was a single-center, entry-into-man, phase 1,
double-blind, randomized, placebo-controlled study (trial registration
EudraCT No. 2007-001181-33) in 10 sequential groups of 8 healthy
male subjects each. In compliance with a randomization list generated
by using computerized techniques, within each group 2 subjects were
randomized to receive placebo and the remaining 6 to receive
etamicastat. Etamicastat was administered as single oral doses of 2,
10, 20, 50, 100, 200, 400, 600, 900 or 1200 mg. Eligible volunteers
were admitted to the unit 2 days prior (Day −2) to receiving the
studymedication (Day 1) and remained in the unit under clinical super-
vision for at least 72 h after dosing (Day 4). During admission, SBP and
DBP and HR were recorded in supine position (after resting for at least
10 min) using a Dinamap® (GE Healthcare) monitor at the following
times: Day−1 (the day prior to dosing) — time 0 (24 h before dosing)
and 1, 2, 3, 4, 5, 6, 8, 10, 12 and 16h after; Day 1 (dosing day)— pre-dose
and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 48, and 72 h post-dose. Orthostatic
blood pressure and HRwere recorded in standing position (after stand-
ing for approximately 2 min) at the following times: Day−1 — time 0
and 2, 4, 8, and 12 h after; Day 1 — pre-dose and 2, 4, 8, 12, and 24 h
post-dose. 12-lead digital ECG were recorded on Day −1 at time 0
and 1, 2, 3, 4, 6, 8, 10, 12 and 16 h after, and on Day 1 at pre-dose and
1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, and 72 h post-dose. Digital ECGs wererecorded after 10 min of rest, in triplicate (with an interval of 5 min,
with a difference of at least 1 min between each of the 3 recordings).
A general safety assessment and detailed pharmacokinetic evaluation
was previously made available [21].
2.2.2.2. Cardiac evaluation after repeated oral administration in young and
elderly healthy volunteers. This was an open-label, single-center,
parallel-group study (trial registration EudraCT No. 2008-002127-82)
in a group of 12 healthy young male subjects and a group of 12 healthy
elderly male subjects. Participants were drawn from the study center's
pool of volunteers. Volunteers eligible for participation were healthy
male volunteers between 18 and 45 years (young group) or 65 years
or more (elderly group), non-smokers or smokers of less than 10 ciga-
rettes per day. Subjects were considered ineligible for participation if
they: had been administered any investigational drug within 90 days,
prescription drug within 30 days or over-the-counter drugs within
7 days before admission; showed to be prone to orthostatic hypo-
tension, deﬁned by a difference between supine SBP and standing SBP
≥20 mm Hg or a difference between supine DBP and standing DBP
≥10 mm Hg; or presented a ECG QTc interval reading ≥450 ms
(young subjects) or ≥470 ms (elderly subjects). The trial consisted of
a 100 mg etamicastat multiple-dose period during which participants
received 100 mg etamicastat once-daily, for 7 days. A general safety as-
sessment and detailed pharmacokinetic evaluation was previously
made available [23].
2.2.2.3. Cardiac evaluation after repeated oral administration in hypertensive
patients. This was a Phase IIa, double-blind, randomized, placebo-
controlled study (trial registration EudraCTNo. 2008-002789-69) investi-
gating three dosage regimens of etamicastat (50, 100 or 200 mg, once-
daily, for 10 days) in 3 groups of 8 hypertensive male patients aged
between 18 and 45 years. Within each group, it was planned to random-
ize 2 subjects to receive placebo and the remaining 6 subjects to receive
etamicastat. Randomization was performed by means of computerized
techniques. Doses of 50, 100 and 200mg of etamicastatwere investigated
in ascending order. The decision to proceed to the next dose depended on
the tolerability assessment of the previous dose level. Each patient partic-
ipated in the study for approximately 8 weeks. Participation included
several screening evaluations within 4 weeks before admission to an in-
patient period (Day−1 to Day 11), two ambulatory visits (Days 12 and
13) and a follow-up visit 7 to 10 days after the last administration. During
the screening period, subjects received placebo once daily, in the morn-
ing, in a single-blind manner (subjects did not know they were receiving
placebo, but the investigator was aware). Patients were admitted to the
research facility in themorning of Day−1 (day before theﬁrst dose of in-
vestigational product) and remained inpatient until at least 24 h after the
last dose, on Day 11. Then patients were discharged and instructed to
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Fig. 3. Inhibition curve for blockade of hERG relative tail current by etamicastat. Values are
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During the inpatient period, from Day 1 to Day 10, participants received
in a double-blind fashion either etamicastat 50, 100 or 200mg or placebo,
once daily, in the morning, with 250 ml water, under fasting conditions.
Patients remained fasted until 4 h post-dose on Days 1 and 10, and until
1 h post-dose on Days 2 to 9. A general safety assessment and detailed
pharmacokinetic evaluation was previously made available [20].
Safety was assessed from reported AEs, physical examination, vital
signs, digital 12-lead ECG, and clinical laboratory test results. HIV and
hepatitis B and C serology, and drugs of abuse screen were performed
at screening; alcohol test was performed at screening and Day−1. Lab-
oratory safety tests (hematology, blood chemistry and urinalysis) were
performed at screening, Day−1, pre-dose onDays 5 and 10, Day 13 and
follow-up visit.
Digital 12-leadECG recordingswere taken in supine position, after at
least a 10-minute rest, at the screening visit and then at the following
times: Day −1: time 0 (24 h before ﬁrst dosing), and 1, 2, 3, 4, 6, 8,
10, 12 and 16 h after; Day 1 (day of ﬁrst dosing): pre-dose, and 1, 2, 3,
4, 6, 8, 10, 12 and 16 h post-dose; from Day 2 to Day 9: pre-dose and
2 h post-dose; Day 10 (day of last dosing): pre-dose, and 1, 2, 3, 4, 6,
8, 10, 12, 16, 24, 48 and 72 h post-dose. The reported 12-lead ECG
parameters included HR, PR interval, QRS interval duration and axis
deviation, and QT interval. QT interval was corrected by the Fridericia's
(QTcF) formula. The primary method of correction was QTcF. A manualTable 1
Mean arterial blood pressure (MABP), RR interval and QTcQ interval of the electrocardiogram
conscious Cynomolgusmonkey monitored by telemetry.
Etamicastat (mg/kg) Measurement times before and after administration (h)
−0.5 1 2 4 6
MABP (mm Hg)
0 80 ± 3 82 ± 6 78 ± 4 79 ± 5
15 mg/kg 79 ± 4 78 ± 4 88 ± 8 74 ± 2
45 mg/kg 81 ± 7 83 ± 6 89 ± 7 74 ± 8
90 mg/kg 83 ± 9 80 ± 7 85 ± 10 77 ± 6
RR interval (ms)
0 405 ± 40 430 ± 6 461 ± 32 420 ± 16 4
15 mg/kg 421 ± 22 455 ± 9 417 ± 17 465 ± 19 4
45 mg/kg 395 ± 30 422 ± 34 431 ± 27 454 ± 28 4
90 mg/kg 385 ± 18 428 ± 11 398 ± 28 423 ± 18 4
QTcQ interval (ms)
0 250 ± 2 242 ± 7 248 ± 8 247 ± 7 2
15 mg/kg 242 ± 5 248 ± 4 255 ± 3 246 ± 6 2
45 mg/kg 253 ± 9 252 ± 11 253 ± 8 251 ± 11 2
90 mg/kg 249 ± 6 247 ± 5 252 ± 5 253 ± 3 2
The placebo and etamicastat were administered orally, by capsule, at time 0. Values are mean
⁎ Denotes P b 0.05 etamicastat vs vehicle.reading of the digital ECGs was used to assess QT/QTc interval
prolongation.
Safety standing blood pressure and HR measurements taken after
the patient had been standing for 2 min were performed on Day−1,
and at pre-dose and 2, 12 and 24 h post ﬁrst (Day 1) and last dose
(Day 10).
2.3. Assay of etamicastat and metabolites in plasma
Plasma concentrations of etamicastat and BIA 5–961were determined
using a validated method consisting of reversed phase liquid chroma-
tography coupled with triple-stage quadrupole mass-spectrometric
detection (LC/MS–MS), as previously described [26]. In brief, for the
preparation of calibration samples, etamicastat and BIA 5–961were dis-
solved inmethanol to a ﬁnal concentration of 250 μg/ml (plasma assay).
For the quality control (QC) samples, a second set of stock solutionswas
prepared. For calibration and QC samples, working solutions in metha-
nolwere added to plasmausing a ratio of 2/98 (v/v). For the preparation
of the internal standard (ISTD) solution for the plasma assay, reference
standard (BIA 5–1058,molecular formula C21H21F2N3OS)was dissolved
in methanol to a concentration of 1000 μg/ml and then diluted in
methanol to 5000 ng/ml; further dilutions to a ﬁnal concentration of
50 ng/ml were done using acetonitrile/ethanol (50/50, v/v). For the
preparation of the ISTD solution for the urine assays, reference standard
was dissolved in methanol to a ﬁnal concentration of 50 ng/ml. Plasma
samples were vortexed and centrifuged for 20 min at approximately
3362 g and approximately 8 °C after unassisted thawing at room tem-
perature. To an aliquot of 100 μl of plasma, 300 μl of acetonitrile/ethanol
(50/50, v/v) containing 50 ng/ml of ISTD were added. After protein
precipitation at room temperature, plasma samples were ﬁltrated
using a Captiva ﬁlter plate and an aliquot of 5 μl of the ﬁltrate was
injected onto the analytical column. To an aliquot of 20 μl of urine,
80 μl lithium-heparin plasma was added and were precipitated by
300 μl of methanol containing the ISTD. After protein precipitation at
room temperature, urine samples were centrifuged for 20 min at
2773 g and 8 °C. An aliquot of 250 μl of the supernatant was transferred
into an ultraﬁltration ﬁlter plate and centrifuged for about 2 h at
4000 rpm (2773 g) and approximately 20 °C. An aliquot of 5 μl was
injected onto the analytical column. The samples were stored in the
autosampler tray at approximately 8 °C ± 5 °C.
The analytical equipment consisted of a Rheos 2000 pump (Flux
Instruments, Basel, Switzerland), a SpeedROD, RP18e, 50–4.6 mm
analytical column (Merck, Darmstadt, Germany), a ultra-low volumefollowing oral administration of vehicle, then etamicastat at 15, 45 and 90 mg/kg in the
8 10 14 18 22
75 ± 4 78 ± 5 60 ± 6 64 ± 4 65 ± 5 79 ± 6
74 ± 6 77 ± 4 59 ± 4 64 ± 3 65 ± 3 76 ± 6
73 ± 6 76 ± 7 58 ± 6 59 ± 5 65 ± 6 74 ± 6
72 ± 6 76 ± 7 61 ± 7 64 ± 6 64 ± 5 68 ± 7⁎
12 ± 21 436 ± 14 572 ± 10 603 ± 38 613 ± 24 412 ± 39
29 ± 26 446 ± 11 592 ± 31 621 ± 51 602 ± 30 426 ± 18
45 ± 22 438 ± 16 596 ± 20 666 ± 26 588 ± 4 407 ± 20
70 ± 28 456 ± 4 552 ± 20 588 ± 43 561 ± 37 464 ± 16
51 ± 8 245 ± 5 251 ± 5 254 ± 7 253 ± 5 247 ± 6
46 ± 5 241 ± 4 245 ± 9 236 ± 5 245 ± 12 266 ± 15
47 ± 9 243 ± 11 248 ± 13 252 ± 10 251 ± 13 259 ± 5
41 ± 6 239 ± 2 257 ± 10 251 ± 9 254 ± 10 242 ± 6
± SEM of results obtained from 4 animals.
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TSQ Quantum mass spectrometer (Thermo Fisher Scientiﬁc, San Jose,
CA, USA), and a HTS PAL autosampler (CTC Analytics AG, Zurich,
Switzerland). The MS detector was operated in positive ion mode with
mass transitions for etamicastat, BIA 5–961 and the ISTD of respectively
283.0 amu, 127.0 amu and 120.0 amu. Column temperature was 50 °C.
The mobile phases used water containing 0.5% formic acid (phase A),
water containing 1.0% formic acid (phase B), acetonitrile containing
1.0% formic acid (phase C) and acetonitrile containing 0.01% formic
acid (phase D). Calibration curves over the nominal concentration
range 5–5000 ng/ml for plasma assays and a set of quality control
(QC) samples were analyzed with each batch of study samples. The
QC samples were prepared in duplicates at three concentration levels
(low, medium and high). The analytical method was demonstrated to
be precise and accurate. The descriptive statistics of the QC samples
showed that the overall imprecision of the method, measured by the0 4 8 12 16 20 24
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Fig. 4. Effects of placebo and etamicastat on arterial blood pressure, heart rate, and themain pa
oral (p.o. capsule) administration in the conscious male Cynomolgus primate monitored by teleinter-batch coefﬁcient of variation, was ≤7.1% for etamicastat and
≤7.5% for BIA 5–961. The inter-batch accuracy ranged from 101.5% to
105.3% for etamicastat and 101.0% to 105.3% for BIA 5–961. The lower
limit of quantiﬁcation of the assay (LLOQ) was 5 ng/ml in plasma, for
both compounds.
2.4. Statistical analysis
Reported values are expressed as means ± standard error of the
mean (SEM) ormeanswith conﬁdence intervals (CI). Statistical analysis
was performed using the Dynamic Microsystem software GB-Stat
version 6.5. For in vitro (hERG) study, multisample analysis (ANOVA
followed byDunnett's test)was performed to test statistical signiﬁcance
of all concentrations tested. For in vivo (telemetry) studies, intra-group
comparison was performed using an one-way analysis of variance
(time) with repeated measures at each time, followed by Dunnett's t0 4 8 12 16 20 24
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rameters of the electrocardiogram (PR interval, QRS duration and QTcF interval) following
metry. Symbols represent mean ± SEM values of values of 4 animals per group.
Table 2
ECG parameters in female and male Cynomolgusmonkeys before and following oral administration of vehicle and etamicastat at 15 and 45 mg/kg.
Heart rate (bpm) P amplitude (mV) P duration (ms) P–Q interval (ms) QRS interval (ms) Q–T interval (ms)
Pre-test
Vehicle (0 mg/kg/day) Females 243 ± 20 0.09 ± 0.02 41 ± 2 58 ± 4 50 ± 0 180 ± 11
Males 227 ± 46 0.10 ± 0.00 43 ± 5 64 ± 7 52 ± 4 180 ± 21
Etamicastat (15 mg/kg/day) Females 250 ± 8 0.09 ± 0.01 46 ± 5 60 ± 0 50 ± 0 173 ± 10
Males 258 ± 17 0.10 ± 0.01 44 ± 5 60 ± 8 53 ± 5 170 ± 8
Etamicastat (45 mg/kg/day) Females 223 ± 23 0.10 ± 0.00 43 ± 5 63 ± 9 55 ± 6* 185 ± 13
Males 263 ± 24 0.06 ± 0.03* 44 ± 3 63 ± 5 50 ± 0 166 ± 8
Week 1
Vehicle (0 mg/kg/day) before dosing Females 237 ± 26 0.09 ± 0.03 40 ± 0 60 ± 0 50 ± 0 183 ± 15
1 h after dosing 258 ± 21 0.08 ± 0.02 40 ± 0 59 ± 2 51 ± 2 178 ± 12
before dosing Males 238 ± 42 0.11 ± 0.02 44 ± 4 66 ± 8 57 ± 5 183 ± 14
1 h after dosing 238 ± 31 0.10 ± 0.03 46 ± 5 67 ± 8 53 ± 5 180 ± 11
Etamicastat (15 mg/kg/day) before dosing Females 245 ± 6 0.09 ± 0.01 41 ± 3 63 ± 3 50 ± 0 183 ± 5
1 h after dosing 233 ± 21 0.08 ± 0.05 43 ± 3 65 ± 4 53 ± 5 185 ± 10
before dosing Males 240 ± 41 0.08 ± 0.03 43 ± 5 56 ± 5 53 ± 5 176 ± 11
1 h after dosing 225 ± 31 0.09 ± 0.01 40 ± 0 60 ± 0 53 ± 5 180 ± 12
Etamicastat (45 mg/kg/day) before dosing Females 225 ± 39 0.10 ± 0.01 48 ± 10 68 ± 10 53 ± 5 190 ± 18
1 h after dosing 208 ± 30* 0.09 ± 0.03 43 ± 5 64 ± 8 50 ± 0 198 ± 17
before dosing Males 220 ± 40 0.09 ± 0.01 40 ± 0 63 ± 5 53 ± 5 190 ± 20
1 h after dosing 233 ± 22 0.09 ± 0.03 43 ± 5 63 ± 5 55 ± 6 193 ± 15
Week 13
Vehicle (0 mg/kg/day) before dosing Females 252 ± 18 0.09 ± 0.02 40 ± 0 58 ± 4 58 ± 4 177 ± 12
1 h after dosing 230 ± 24 0.07 ± 0.02 40 ± 0 58 ± 4 58 ± 4 187 ± 21
before dosing Males 246 ± 36 0.12 ± 0.07 42 ± 4 61 ± 5 60 ± 0 183 ± 15
1 h after dosing 210 ± 44 0.10 ± 0.03 45 ± 5 67 ± 8 60 ± 0 197 ± 26
Etamicastat (15 mg/kg/day) before dosing Females 240 ± 24 0.10 ± 0.01 41 ± 3 59 ± 3 60 ± 0 190 ± 12
1 h after dosing 218 ± 15 0.10 ± 0.01 44 ± 5 63 ± 5 60 ± 0 200 ± 0
before dosing Males 250 ± 22 0.08 ± 0.03 40 ± 0 59 ± 3 60 ± 0 185 ± 13
1 h after dosing 225 ± 44 0.08 ± 0.03 40 ± 0 60 ± 0 60 ± 0 193 ± 22
Etamicastat (45 mg/kg/day) before dosing Females 213 ± 49 0.11 ± 0.02 40 ± 0 59 ± 3 63 ± 5 195 ± 31
1 h after dosing 203 ± 25 0.10 ± 0.01 43 ± 5 68 ± 10# 63 ± 5 203 ± 17
before dosing Males 253 ± 38 0.10 ± 0.00 43 ± 5 59 ± 3 60 ± 0 180 ± 14
1 h after dosing 243 ± 38 0.08 ± 0.02 43 ± 5 63 ± 5 60 ± 0 183 ± 21
Values are means ± SEM. Signiﬁcantly different from corresponding values in vehicle treated animals (*P b 0.05) following Dunnett test.
Signiﬁcantly different from corresponding values before dosing 1 (#P b 0.05) following Dunnett test.
16 M. Vaz-da-Silva et al. / IJC Metabolic & Endocrine 7 (2015) 10–24test in case of signiﬁcant time effect, to compare each time value with
the T0 values (i.e. basal value before each treatment). Inter-group statis-
tical analysis was also performed using a two-way analysis of variance
(group, time) with repeated measures at each time, followed by a
one-way analysis of variance (group) at each time in case of signiﬁcant
group × time interaction. The analysis was completed by Dunnett's t
tests where the group effect was signiﬁcant. In case of data considered
invalid or missing data, the retained value was taken 5 min before or0 4 8 12 16 20 24
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2.5. Drugs
Etamicastat, BIA 5–961 and reference standard (BIA 5–1058) were
supplied by BIAL (Laboratory of Chemistry, S. Mamede do Coronado,
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Table 3
Pharmacokinetic parameters of etamicastat in female and male Cynomolgusmonkeys after single and 91 once daily administrations of etamicastat by oral gavage.
Day 1 Day 91
Dose (mg/kg) 15 45 Ratio 15 45 Ratio
Females
Cmax (ng/ml) 686.0 ± 118.8 2497.5 ± 284.3 4.3 ± 1.4 868.8 ± 122.3 3145.0 ± 228.5 3.9 ± 0.7
tmax (h) 2.5 ± 0.5 3.5 ± 0.5 1.6 ± 0.4 3.5 ± 0.5 4.0 ± 0.0 1.3 ± 0.3
AUC0–24 (ng·h/ml) 5591.8 ± 1014.5 23022.0 ± 1898.3 4.9 ± 1.5 6688.0 ± 1016.4 26180.8 ± 943.0 4.2 ± 0.7
AUC0-∞ (ng·h/ml) 6136.0 ± 1130.7 25678.3 ± 2336.9 5.1 ± 1.6 7142.0 ± 1150.3 28024.5 ± 989.9 4.3 ± 0.7
t½ (h) 6.9 ± 0.3 6.9 ± 0.4 1.0 ± 0.1 6.0 ± 0.3 5.8 ± 0.1 1.0 ± 0.0
Males
Cmax (ng/ml) 935.5 ± 71.4 1875.0 ± 179.8 2.0 ± 0.0 834.3 ± 101.7 2895.0 ± 306.9 3.5 ± 0.2
tmax (h) 3.0 ± 0.6 3.5 ± 0.5 1.3 ± 0.3 3.5 ± 0.5 3.0 ± 0.6 0.9 ± 0.1
AUC0–24 (ng·h/ml) 7902.0 ± 339.7 16137.8 ± 2294.1 2.0 ± 0.2 7125.0 ± 1159.0 24168.8 ± 1426.4 3.7 ± 0.7
AUC0–∞ (ng·h/ml) 8873.5 ± 358.0 18549.3 ± 2787.9 2.1 ± 0.3 7671.3 ± 1232.2 25662.8 ± 1420.6 3.7 ± 0.6
t½ (h) 7.4 ± 0.4 7.4 ± 0.7 1.0 ± 0.1 6.4 ± 0.4 5.6 ± 0.4 0.9 ± 0.1
Values are means ± SEM of 4 animals per group.
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3.1. In vitro studies
3.1.1. DβH activity
The experimental conditions, for evaluating the conversion of
tyramine into octopamine by human SK-N-SH cell homogenates, were
previously optimized with time and protein dependency experiments
(data not shown). The formation of octopamine was dependent on the
incubation time up to 1 h (r2 = 0.998) and on protein amount up to
125 μg total protein per assay (r2 = 0.995). With 75 μg total protein
and 45 min incubation time, octopamine was formed by SK-N-SH cell
homogenates with a Km value of 9 (CI, 6; 13) mM for tyramine and a
Vmax of 1725 ± 76 nmol/mg protein/h. Under these optimized condi-
tions, etamicastat and nepicastat inhibited SK-N-SH DβH activity in a
concentration dependent manner (Fig. 2) with IC50 values (in ng/ml)
of 37.2 (CI, 30.7; 44.9) and 13.3 (CI, 11.6; 15.4), respectively.3.1.2. hERG K+ channel
Etamicastat and nepicastat produced reductions of hERG current
amplitude (Fig. 3) with IC50 values (μg/ml) of 44.0 (CI, 34.8; 55.7) and
5.6 (CI, 4.7; 6.5), respectively. In comparison, the positive control sub-
stance E-4031 at 100 nM markedly blocked the hERG tail current
(8.88 ± 1.65% relative tail current). The observed inhibition of hERG
tail currents by E-4031was in linewith its known pharmacological pro-
ﬁle [27].Table 4
Summary statistics of demographic and baseline characteristics of study participating human s
Study Etamicastat group (n) Age (years) Height (cm) Wei
Single ascending
dose study
Placebo (20) 30.8 (19–44) 178.2 (166–195) 72
2 mg (6) 32.0 (21–38) 182.5 (173–194) 82
10 mg (6) 30.3 (20–44) 182.2 (175–191) 79
20 mg (6) 26.8 (19–32) 178.8 (170–186) 66
50 mg (6) 28.8 (20–36) 175.7 (173–179) 70
100 mg (6) 29.8 (19–40) 175.5 (171–183) 68
200 mg (6) 30.7 (20–42) 176.3 (169–191) 72
400 mg (6) 28.2 (25–32) 173.2 (167–181) 70
600 mg (6) 31.3 (22–41) 174.7 (161–183) 74
900 mg (6) 37.7 (22–43) 172.0 (164–178) 64
1200 mg (6) 31.7 (19–38) 179.0 (172–184) 77
Young & elderly
study
100 mg Young group (13) 32.6 (18–44) 175.8 (162–185) 79.0
100 mg Elderly group (12) 69.3 (65–75) 166.9 (160–179) 69.2
Hypertensive
patients study
Placebo (5) 59.6 (53–64) 169 (162–180) 83.2
50 mg (5) 55.8 (51–61) 177 (169–184) 84.3
100 mg (6) 56.5 (49–64) 176 (168–181) 84.8
200 mg (6) 59.8 (58–61) 171 (165–179) 83.3
BMI, body mass index; SBP, supine systolic blood pressure; DBP, supine diastolic blood pressur
Values are means with range values in parenthesis.3.2. In vivo studies
3.2.1. Cynomolgus primates monitored by telemetry
The effects of etamicastat (15, 45 and 90 mg/kg) on arterial blood
pressure, heart rate and the main parameters of the electrocardiogram
were evaluated following oral (p.o. capsule) administration in the con-
scious male Cynomolgus primate monitored by telemetry (Table 1 and
Fig. 4). The doses of etamicastat were based on the results from a max-
imum tolerated dose (MTD) study in Cynomolgusmonkeys inwhich the
MTDwas established as 120mg/kg/day (BIAL data on ﬁle). There was 1
treatment group of 4 primates following a 4 × 4 Latin square design.
There was a washout period of 1 week between each treatment. Ani-
mals were dosed at approximately the same time each day. Venous
blood samples (approximately 1ml) for determination of test substance
in plasma were taken prior to dosing and at 2 and 4 h after the start of
dose administration, or as close as was reasonably practicable to these
time points. Loose feces were noted in the cage of 1 animal following
the administration of 90mg/kg etamicastat. Although thiswas an isolat-
ed incidence in a single animal, it was observed following the highest
dose of test substance and therefore may be related to etamicastat
administration.
Arterial blood pressure (SBP, DBP andMBP)was generally unaffected
following the administration of etamicastat at any of the doses examined
with the exception of a non-statistically signiﬁcant increase 2 h follow-
ing the administration of 15, 45 and 90 mg/kg etamicastat (Table 1
and Fig. 4). However, the magnitude of these changes were small,
reﬂecting increases from pre-dose baseline in MBP of 12.1 ± 8.3%,ubjects.
ght (kg) BMI (kg/m2) SBP (mm Hg) DBP (mm Hg) HR (bpm)
(61–92) 22.7 (20.4–27.1) 106 (86–116) 61 (46–73) 54 (38–70)
(68–97) 24.7 (18.1–29.9) 116 (102–127) 68 (60–80) 60 (44–70)
(72–90) 23.7 (20.8–25.8) 107 (96–113) 62 (57–70) 48 (40–55)
(56–75) 20.6 (18.5–21.7) 99 (88–107) 56 (53–63) 52 (44–62)
(62–81) 22.5 (20.2–25.3) 111 (100–120) 58 (47–66) 57 (45–80)
(60–80) 21.9 (18.8–25.8) 104 (95–111) 55 (50–58) 56 (53–61)
(63–83) 23.2 (21.7–25.1) 109 (96–144) 60 (56–74) 58 (46–70)
(60–79) 23.5 (21.0–26.9) 119 (102–146) 60 (53–66) 59 (47–80)
(63–84) 24.3 (22.7–26.8) 114 (97–138) 59 (51–69) 74 (63–84)
(852–73) 21.5 (19.0–25.6) 107 (102–117) 61 (46–68) 60 (48–72)
(63–88) 23.8 (21.3–26.5) 111 (99–123) 57 (49–61) 61 (57–66)
(57.0–102) 25.8 (20.9–34.4) 117 (103–137) 61 (50–75) 58 (47–70)
(52–86) 25.2 (19.8–29.0) 115 (98–143) 64 (56–68) 66 (52–76)
(74–102) 29.0 (25.0–33.5) 160.6 (123–174) 92.6 (89–99) 70.7 (55–82)
(64–101) 26.8 (22.4–32.2) 150.2 (141–161) 94.0 (84–99) 64.5 (56–68)
(73–101) 27.3 (24.1–30.8) 164.8 (151–187) 96.8 (86–109) 63.8 (55–72)
(71–105) 28.3 (24.6–32.8) 147.2 (129–163) 87.2 (78–93) 60.0 (49–72)
e; HR; heart rate beats per min.
18 M. Vaz-da-Silva et al. / IJC Metabolic & Endocrine 7 (2015) 10–2410.2 ± 5.2% and 2.3 ± 4.0% following 15, 45 and 90 mg/kg etamicastat
administration, respectively, in comparison to a decrease of 2.0 ± 1.5%
at this time following placebo treatment and were mainly due to an
increase in the arterial blood pressure of a single animal (Table 1).
Furthermore, no dose-dependency was evident, consequently, the
observed increaseswere not considered to be etamicastat related. In ad-
dition, a decrease in arterial blood pressure was evident 22 h following
the administration of 90mg/kg etamicastat (P b 0.05 for DBP andMBP)
(Fig. 4B). At this time, arterial blood pressure wasmaintained at similar
values to those observed throughout the dark phase of the animals'0 2 10 20 50 100 200 400 600 900 1200
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Fig. 6.Mean change from baseline of supine systolic blood pressure, diastolic blood pressure, h
healthy subjects after single once-daily administration of etamicastat. Symbols represent mean
before dosing (#P b 0.05) following Dunnett test.light/dark cycle, was within the range of values observed following pla-
cebo treatment and as this decrease was noted some considerable time
following an oral dose, it was not considered to be related to the admin-
istration of etamicastat.
HR was noted to be slightly elevated, although not signiﬁcantly, in
comparison to placebo at 2 h following the administration of 15, 45
and 90 mg/kg etamicastat (Fig. 4C). However, when compared to pre-
dose baseline values, this increasewas no longer evident. HRwas other-
wise unaffected following the administration of etamicastat with the
exception of a tendency for this parameter to be decreased 14 h0 2 10 20 50 100 200 400 600 900 1200
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19M. Vaz-da-Silva et al. / IJC Metabolic & Endocrine 7 (2015) 10–24following the administration of 45 mg/kg etamicastat. As this was an
isolated incidence, not observed following the highest dose of etami-
castat and was noted some time following an oral administration, it
was not considered to be etamicastat related. RR interval was generally
unaffected following the administration of etamicastat with the excep-
tion of changes concomitant with those observed in HR (Table 1).
Similarly, and for reasons discussed for HR, these changes were not
considered to be related to the administration of etamicastat. PR interval
and QRS duration were unaffected following the administration of eta-
micastat at any of the doses examined (Fig. 4E).
There was no marked effect on QT interval following the adminis-
tration of 15, 45 or 90 mg/kg etamicastat with the exception of a pro-
longation 14 h following the administration of 45 mg/kg etamicastat,
corresponding with the changes observed in heart rate and RR interval
at this time. When the QT interval was corrected for changes in HR/RR
interval by calculation of the QTcF interval (Fig. 4F), this prolongation,
although not signiﬁcant, was still observed; however, when corrected
using the individual animal speciﬁc correction formula, QTcQ, it was
no longer apparent (Table 1). A slight shortening of the QTcQ interval
was noted at 14 h following the administration of 15mg/kg etamicastat
when compared to placebo (Table 1). However, values remained un-
changed when compared to pre-dose baseline; therefore, this was not
considered to be a drug-related effect.
Mean plasma concentrations of etamicastat at 2 and 4 h were
610 ± 160 and 646 ± 68, 771 ± 304 and 1968 ± 356, and 1055 ±
76.5 and 1926 ± 592 ng/ml at the dose levels of 15, 45 and
90 mg/kg, respectively.3.2.2. Cardiac evaluation after repeated oral administration in
Cynomolgus primates
In this set of experiments, cumulative effects of etamicastat were
assessed in the female andmale Cynomolgusmonkeys followingoral ad-
ministration by gastric gavage once daily for at least 91 days. Animals
received etamicastat at 0, 15 or 45 mg/kg/day; the control group only
received distilled water as vehicle. Diarrhea and soft feces were fre-
quently observed in groups receiving 15 or 45 mg/kg/day etamicastat.
In all groups, no treatment-related ophthalmoscopic alteration was
recorded. No effects resulting from treatment with etamicastat were
observed on hematology, biochemistry or urinalysis. There were no
treatment-related ﬁndings in the electrocardiograms (heart rate, P
amplitude, P duration, P–Q interval, QRS interval and Q–T interval)Table 5
Summary pharmacokinetic parameters of etamicastat.
Study Etamicastat group (n) Cmax (ng/ml) Cmin (ng
Single ascending dose study Placebo (20) ND ND
2 mg (6) ND ND
10 mg (6) 6 ± 1 ND
20 mg (6) 23 ± 8 6.1 ± 1
50 mg (6) 49 ± 13 6.1 ± 1
100 mg (6) 106 ± 24 6.3 ± 0
200 mg (6) 202 ± 24 7.0 ± 1
400 mg (6) 475 ± 119 9.9 ± 2
600 mg (6) 766 ± 161 10.5 ±
900 mg (6) 1469 ± 327 26.6 ±
1200 mg (6) 1638 ± 423 26.7 ±
Young & Elderly studya 100 mg Young group (13) 105 ± 37 15.0 ±
100 mg Elderly group (12) 124 ± 33 18.5 ±
Hypertensive studyb Placebo (5) ND ND
50 mg (5) 62 ± 24 12.7 ±
100 mg (6) 168 ± 56 14.3 ±
200 mg (6) 277 ± 118 16.5 ±
ND = not detected.
Values are means ± SD or means with range values in parenthesis.
a PK parameters refer to last day of once-daily administration = 7 days.
b PK parameters refer to last day of once-daily administration = 10 days.(Table 2). Occasional incidences of incomplete right bundle branch
blockwere observed in three vehicle-treated animals and sinus arrhyth-
mia was observed in two vehicle-treated and one animal receiving
45 mg/kg/day etamicastat. These were considered not related to treat-
ment with etamicastat as they were seen at similar incidences in both
groups and also observed during acclimatization.
Plasma samples were obtained on Day 1 and in Day 91 of the treat-
ment period at 0 (pre-dose) 1, 2, 4, 8, 12 and 24 h after the administra-
tion of etamicastat. All samples were analyzed for concentrations of
etamicastat. All plasma concentrations of etamicastat in male and fe-
malemonkeys receiving only vehiclewere below the limit of quantiﬁca-
tion (5 ng/ml). All animals in the treated dose groups were consistently
exposed to etamicastat after single and repeated oral (gavage) adminis-
tration. The number of quantiﬁable samples was sufﬁcient to calculate
AUC0–t, tmax, Cmax, and t½,z, from the concentration versus time proﬁles
(Fig. 5) and to investigate the effects of dose, gender and single versus
repeated administration on exposure.Maximumplasma concentrations
(Cmax) of etamicastat in female and male monkeys in all groups were
reached 1 to 8 h after administration (Table 3). After tmax, plasma con-
centrations declined rapidly (Fig. 5) with half-lives ranging between
5.0 and 8.4 h (Table 3). Throughout all groups, mean half-lives seemed
to be dose, gender or time independent. After single administration of
etamicastat from 15 to 45 mg/kg/day with 3.0-fold dose increase, ex-
posure to etamicastat in males increased less than expected the given
dose increase: AUC0–t increased by a factor of 2.0 ± 0.6. A similar
increase was observed for Cmax (ratio of 2.0 ± 0.5). In females, from
15 to 45 mg/kg/day AUC0–t and Cmax increased more than dose-
proportionally (ratios of 4.1 ± 1.6 and 3.6 ± 1.5, respectively). After
13 weeks of repeated treatment, from 15 to 45 mg/kg/day with 3.0-
fold dose increase, exposure to etamicastat in both gender increased
more than dose-proportionally: AUC0–t and Cmax increased by a factor
of 3.9 ± 1.2 and 3.6 ± 1.1 for females and 3.4 ± 1.2 to 3.5 ± 1.1 for
males, respectively. Throughout all groups, half-lives seemed to be
dose-independent (half-lives ratios of 0.9 ± 0.2 to 1.0 ± 0.1).3.2.3. Cardiac evaluation after single ascending administration in young
healthy humans
A total of 128 male subjects were screened in order to include 80
subjects in 10 successive groups of 8 subjects each. All 80 included sub-
jects were randomized and completed the study. There was no subject
withdrawal or premature discontinuation. No relevant differences in/ml) tmax (h) AUC0–t (ng·h/ml) AUC0–∞ (ng·h/ml) t1/2 (h)
ND ND ND ND
ND ND ND ND
2.0 (1.0–2.0) 4 ± 2 ND ND
.5 1.0 (0.5–2.0) 84 ± 36 148 ± 25 6.6 ± 1.6
.2 1.0 (0.5–2.0) 304 ± 181 421 ± 238 12.6 ± 6.0
.9 1.5 (1.0–3.0) 957 ± 212 1134 ± 250 19.7 ± 5.7
.5 1.0 (1.0–3.0) 2026 ± 663 2230 ± 701 19.8 ± 3.3
.5 2.0 (1.0–2.1) 3914 ± 1637 4171 ± 1733 17.3 ± 3.7
4.9 3.0 (1.0–5.0) 7111 ± 2480 7355 ± 2566 15.7 ± 1.6
9.4 3.0 (1.0–5.0) 14197 ± 4231 14908 ± 4428 18.8 ± 1.5
17.1 2.5 (1.0–3.0) 13997 ± 5687 14707 ± 6147 18.2 ± 1.6
11.1 1.5 (1.0–4.0) 1142 ± 692 1497 ± 825 17.3 ± 5.8
11.9 1.0 (0.5–5.0) 1666 ± 1026 2199 ± 1262 28.1 ± 12.2
ND ND ND ND
2.0 1.0 (0.5–2.0) 769 ± 456 1123 ± 676 18.5 ± 9.5
3.2 1.0 (0.5–2.0) 2387 ± 1366 2906 ± 1603 24.6 ± 9.2
5.9 1.0 (1.0–2.0) 3633 ± 1845 4307 ± 2050 28.0 ± 3.1
20 M. Vaz-da-Silva et al. / IJC Metabolic & Endocrine 7 (2015) 10–24demographic characteristics were found between the treatment groups
(Table 4). Fig. 6 displays the maximum change from baseline of supine
SBP, DBP, HR and QTcF interval in young healthy subjects after once-
daily single administration of placebo or etamicastat (2 to 1200 mg).0 4 8 12 16 20 24 30 60 90 120
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etamicastat and BIA 5–961 in young and elderly healthy subjects after once-daily administrat
and 13 subjects per group. Signiﬁcantly different from corresponding values before dosing (*PThere was no clinically signiﬁcant change in SBP, DBP, HR and QTcF in-
terval, though important variability was observed. A total of 18 AEs
were reported in 13 subjects. There was no serious AE and no TEAE re-
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b 0.05) following Dunnett test.
21M. Vaz-da-Silva et al. / IJC Metabolic & Endocrine 7 (2015) 10–24intensity. Etamicastat was well tolerated at all the investigated dose
levels. Mean Cmax and area under the plasma concentrations versus
time curve from time 0 to inﬁnity (AUC0–∞) etamicastat plasma levels
following single doses of 2, 10, 20, 50, 100, 200, 400, 600, 900 and
1200mg of etamicastat are displayed in Fig. 6. Etamicastat plasma con-
centrations could not be detected at the 2 mg dose level and wereFig. 8.Mean change from baseline of supine systolic blood pressure, diastolic blood pressure, h
etamicastat andBIA 5–961 inhypertensive subjects after once-daily administration of placebo o
of 12 and 13 subjects per group.detected in only 3 subjects and at very few sampling time-points at
the 10 mg dose level. BIA 5–961 plasma concentrations could only be
detected in two subjects at the 2mg dose, and therefore mean pharma-
cokinetic parameters are only depicted for etamicastat 10mg and above
doses (Fig. 6). The corresponding pharmacokinetic parameters are pre-
sented in Table 5. Although systemic exposure appeared to increaseeart rate, PR interval, QRS duration and QTcF interval, and concentration time proﬁles of
r etamicastat (50, 100 and 200mg/day) for 10days. Symbols representmean±SEMvalues
22 M. Vaz-da-Silva et al. / IJC Metabolic & Endocrine 7 (2015) 10–24close to dose-proportionally to the administered dose (Fig. 6), dose pro-
portionality could not be demonstrated using an exponential regression
model for Cmax or AUC0–∞ of both etamicastat and BIA 5–961.
3.2.4. Cardiac evaluation after repeated administration in young and
elderly healthy humans
In total, 25 subjects (13 young and 12 elderly) were enrolled. Their
demographic and main baseline characteristics are summarized in
Table 4. All subjects were Caucasian but 1 Black in the elderly group.
One young subject was prematurely discontinued due to a serious AE
and was replaced. Twenty-four subjects (12 in each age group) com-
pleted the study. Fig. 7 displays the mean change from baseline of
supine SBP, DBP, HR, PR interval, QRS duration and QTcF interval in
young and elderly healthy subjects after once-daily administrations of
etamicastat for 7 days. There was no clinically signiﬁcant change in su-
pine SBP and DBP in young subjects. However, in elderly subjects, there
was approximately 17mmHg and 11mmHg decreases in SBP and DBP
respectively, peaking 6 to 8 h after the last dosing. No clinically signiﬁ-
cant out-of-range value in vital signs or ECG parameters, HR, PR interval,
QRS duration and QTcF interval were observed in young and elderly
healthy subjects after once-daily administration of etamicastat for
7 days. In the elderly group, a total of 3 AEs were reported (sciatica, as-
thenia, and back pain). One serious AE (myopericarditis) occurred in the
young group. Paracetamol was administered for the treatment of 2 AEs
(sciatica and back pain). All AEs were mild to moderate in intensity but
the myopericarditis was severe and led to the subject's discontinuation
of the study. Myopericarditis occurred after 2 days of repeated dosing
and the subject recovered after 7 days.
Themean plasma concentration-time proﬁles of etamicastat and BIA
5–961 following the last dose of a 100 mg once-daily regimen of
etamicastat for 7 days in elderly and young subjects are displayed in
Fig. 7. The corresponding pharmacokinetic parameters are presented
in Table 5. The systemic exposure to etamicastat, as assessed by Cmax,
AUC during the dosing interval (AUC0–24), AUC0–∞ and minimum ob-
served concentration (Cmin), was not signiﬁcantly different in elderly
and young subjects both following repeated doses of etamicastat. Fol-
lowing multiple doses of etamicastat, BIA 5–961 AUC0–∞ and Cmin
were signiﬁcantly higher in elderly as compared with young subjects.
3.2.5. Cardiac evaluation after repeated administration in
hypertensive patients
A total of 23 male volunteers, with ages between 49 and 64 years,
were randomized and constituted the safety and pharmacokinetic pop-
ulation. All subjects were Caucasian except one Black. One subject
administered 50mgof etamicastatwithdrew onDay 1 due to the occur-
rence of an AE (ECG repolarization abnormality), and 22 completed the
study and constituted the pharmacodynamic population. The demo-
graphic and other baseline characteristics of the study population by
treatment group are summarized in Table 4. No relevant between-
group differences were found. Fig. 8 displays the mean change from
baseline of supine SBP, DBP, HR, PR interval, QRS duration and QTcF in-
terval in hypertensive patients subjects after once-daily administrations
of etamicastat for 10 days. After 10 days of treatment, the decrease of
SBP at day time and night time tended to bemore important in subjects
who had received 50 mg of etamicastat (−7.6 and−7.4 mm Hg, re-
spectively), 100 mg (−9.1 and −10.2 mm Hg, respectively) and
200 mg (−9.7 and −9.2 mm Hg, respectively) than in subjects who
had received placebo (−2.4 and +3.8 mm Hg). After 10 days of treat-
ment, the decrease of DBP at day time and night time also tended to
be more marked in subjects who had received 50 mg of etamicastat
(−5.0 and −3.6 mm Hg, respectively), 100 mg (−5.2 and
−6.8 mm Hg, respectively) and 200 mg (−4.7 and−5.2 mm Hg, re-
spectively) than in subjects who had received placebo (0.0 and
+1.2mmHg). After 10 days of treatment, no clinically relevant changes
of HR at day time and night timewere observed in subjects who had re-
ceived 50 mg of etamicastat (−3.8 and −0.4 bpm, respectively),100 mg (2.3 and 4.8 bpm, respectively) and 200 mg (+0.3 and
−2.5 bpm, respectively) compared to subjects who had received place-
bo (+0.8 and +0.4 bpm, respectively). No clinically signiﬁcant out-of-
range value in vital signs or ECG parameters, HR, PR interval, QRS dura-
tion and QTcF interval were observed in hypertensive subjects after
once-daily administrations of etamicastat, for 10 days. No clinically rel-
evant changes were observed in ECG intervals. In particular, no subject
had a change from baseline in QTcF of more than 60 ms and there was
no signiﬁcant prolongation of QTcF interval N 480 msec.
Ten patients reported a total of 12 TEAEs: 3 AEs (gamma-glutamyl
transferase increase, gout, and diarrhea) in 3 patients with placebo, 1
AE (ECG repolarization abnormality) that led to study discontinuation
on Day 1 in a patient with etamicastat 50 mg, 4 AEs (generalized
maculopapular rash, pain in a extremity, headache, and vasovagal syn-
cope) in 3 patients with etamicastat 100 mg, and 4 AEs (sciatica, pruri-
tus, eczema, and dry skin) in 3 patients with etamicastat 200 mg. The
maculopapular rash was moderate and emerged at Day 10. There
were no serious AEs. All AEs were mild (7 cases) or moderate (5
cases) in intensity and recovered without sequelae.
Themeanplasma concentration-time proﬁles of etamicastat and BIA
5–961 following the last dose of a once-daily regimen of etamicastat for
10 days in hypertensive patients are displayed in Fig. 8. The correspond-
ing pharmacokinetic parameters are presented in Table 5. Etamicastat
Cmax was reached 1 h post-dose and declined thereafter with a mean
t1/2 of 19 to 28 h following repeated administration. Systemic exposure
to etamicastat and BIA 5–961 increased less than dose-proportionally
with increasing doses.
4. Discussion
Both nepicastat and etamicastat markedly inhibited the activity of
native DβH expressed in SK-N-SH human neuroblastoma cells, though
the former was more potent than the later with IC50s of 13.3 and
37.2 ng/ml, respectively. On the other hand, the IC50 value for reduction
of hERG current amplitude by nepicastat (5.6 μg/ml) was 7.9-fold that
observed for etamicastat (44.0 μg/ml). Assuming the ratio of IC50 values
against hERG andDBH as a safetywindow, then etamicastat (IC50 hERG/
DβH = 1183) is expected to offer a signiﬁcant advantage over
nepicastat (IC50 hERG/DβH = 421). This IC50 value of etamicastat
(44.0 μg/ml) against hERG is approximately 28 times higher than the
plasma concentration (1.6 μg/ml) that was found in healthy volunteers
after single administration of 1200 mg, a high well-tolerated dose that
produced ca. 80% inhibition of DβB activity [21].
In conscious telemetered Cynomolgusmonkeys, etamicastat had no
substantial effects on arterial blood pressure, HR and the PR interval
when administered orally at 15, 45 and 90 mg/kg with the exception
of a QT prolongation 14 h following the administration of 45 mg/kg
etamicastat, correspondingwith the changes observed in HR and RR in-
terval at this time. When the QT interval was corrected for changes in
HR/RR interval by calculation of the QTcF interval, this prolongation
was still evident; however, when corrected using the individual animal
speciﬁc correction formula, QTcQ, it was no longer apparent. A slight
shortening of the QTcQ interval was noted at 14 h following the admin-
istration of 15mg/kg etamicastat when compared to vehicle, but values
remained unchanged when compared to pre-dose baseline. Therefore,
this was not considered to be a drug-related effect. No arrhythmia or
other changes in the morphology of the electrocardiogram were
observed at any dose level of etamicastat. Mean plasma concentrations
of etamicastat at 2 and 4 h were 610 and 646, 771 and 1968, and 1055
and 1926 ng/ml at the dose levels of 15, 45 and 90 mg/kg, respectively.
Administered orally at 15 and 45 mg/kg/day in female and male
Cynomolgus monkey for 91 days, etamicastat had no effect on HR and
the waveform or intervals of the electrocardiogram. At the highest
dose level of 45mg/kg/day, mean plasma concentrations of etamicastat
were 1875 (males) or 2497 (females) and 2895 (males) or 3145 ng/ml
(females) on Day 1 and Day 91 of treatment, respectively. Although
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ies, it is not unusual to observe higher plasma concentrations in females
than in males. It is also known that females are more susceptible to
drug-induced long QT interval and cardiac arrhythmias than males
[28,29]. The plasma concentrations measured in monkeys at doses
which did not show any deleterious effects, including ECG disturbance,
were at least 2 times greater than those measured in humans at the
highest cardiovascular active doses (1200mg) or 10 to 15 times greater
than those measured in humans at therapeutic doses (100 to 200 mg).
This ﬁnding is in agreement with that observed in the hERG study: at
1 μg/ml, no effect was found on the hERG mediated current. Only con-
centrations 3 to 10 times higher were necessary to affect the delayed
rectiﬁer potassium channels.
In the single ascending study inwhich young healthy volunteerswere
given once-daily oral doses of placebo or etamicastat from 2 to 1200 mg,
the extent of systemic exposure to etamicastat increased in a close but
not complete dose-proportional manner. Etamicastat Cmax occurred
quickly after administration, at approximately 1 to 3 h after dosing.
Etamicastat elimination appeared to be slower for the highest doses,
with elimination half-lives increasing when the dose increased, from
6.6 h at the 20mg dose to 18.2 h at the 1200mg dose. There was no clin-
ically signiﬁcant change in supine SBP, DBP, HR andQTcF interval, though
important variability and no clear trendwas observed. A total of 18 TEAEs
were reported in 13 subjects. Therewas no serious AE andnoAE required
the withdrawal of a subject. All AEs were mild to moderate in intensity.
The study that investigated the effect of age on the tolerability and
pharmacokinetics of etamicastat in elderly (65 years or older) and
young adult (18–45 years) subjects followed a standard design for a
phase I study in healthy subjects aiming to investigate the effect of age
on the drug pharmacokinetics. This is useful at an early phase of drug
development to deﬁne the dosage regimes to be tested in elderly sub-
jects enrolled in later therapeutic studies. The cardiovascular safety
evaluation comprised changes from baseline of supine SBP, DBP, HR,
PR interval, QRS duration and QTcF interval after once-daily administra-
tion of etamicastat for 7 days. There was no clinically signiﬁcant change
in supine SBP and DBP in young subjects. However, in elderly subjects,
there was approximately 17mmHg and 11mmHg decreases in supine
SBP and DBP, respectively, peaking 6 to 8 h after the last dosing. No clin-
ically signiﬁcant out-of-range value in vital signs or ECGparameters, HR,
PR interval, QRS duration andQTcF intervalwere observed in young and
elderly healthy subjects. The mean plasma concentration-time proﬁles
of etamicastat and BIA 5–961 following the last dose of a 100 mg
once-daily regimen of etamicastat for 7 days indicated that the systemic
exposure to etamicastat, as assessed by Cmax, AUC0–24, AUC0–∞ and Cmin,
was not signiﬁcantly different in elderly and young subjects both fol-
lowing repeated doses of etamicastat. However, the systemic exposure
to BIA 5–961, as assessed by AUC0–∞ and Cmin, were signiﬁcantly higher
in elderly as compared with young subjects.
In hypertensive patients the decrease of SBP at day time and night
time tended to be more marked in subjects who received etamicastat
(50, 100 and 200 mg) than in subjects who received placebo. After
10 days of treatment, the decrease of DBP at day time and night time
also tended to be more marked in subjects who received etamicastat
than in subjects who received placebo. This was accompanied by no
clinically relevant changes of HR at day time and night time in subjects
who received etamicastat (50, 100 and 200 mg) compared to subjects
who received placebo. However, it should be underlined that after the
last dose of 100mg etamicastat there was approximately 17mmHg de-
crease in SBP and 11mmHg decrease in DBP, peaking 3 to 6 h after the
last dosing. No clinically signiﬁcant out-of-range value in vital signs or
ECG parameters, HR, PR interval, QRS duration and QTcF interval were
observed in hypertensive subjects after once-daily administrations of
etamicastat for 10 days. No clinically relevant changes were observed
in ECG intervals. In particular, no subject had a change from baseline
in QTcF of more than 60 ms and there was no signiﬁcant prolongation
of QTcF interval N480 msec.At 100 mg etamicastat, an effective therapeutic dose (ETPC), after
repeated administration (trials in elderly/young healthy subjects and
in hypertensive patients), Cmax (0.124, 0.105 and 0.168 μg/ml, respec-
tively) was reached 1 h post-dose and declined, thereafter, with a
mean half-life (t1/2) of 23 h following the last dose. A 30-foldmargin be-
tween Cmax and hERG IC50 may sufﬁce for drugs currently undergoing
clinical evaluation, but this margin should be increased, particularly
for drugs aimed at non-debilitating diseases [30,31]. Binding of [14C]-
etamicastat to the human plasma proteins was moderate with a mean
of 73.9% (Bial data on ﬁle). As such, the ratio between the 44.0 μg/ml
IC50 for hERG and the 0.035 μg/ml unbound ETPC (44.0/0.044 = 1000)
is 33 times higher the 30-fold safety margin. The no-effect concentra-
tion of 1.0 μg/ml is 23-fold higher than the unbound clinical Cmax
(0.044 μg/ml). As such, the observed in vitro effect in the hERG assay
is highly unlikely to have any clinical impact and this is supported by
the review of Redfern et al. [30], which concluded that a greater than
30-foldmargin between hERG IC50 and unbound clinical Cmax was sufﬁ-
ciently reassuring.
In conclusion, the blockade of hERG current amplitude by etami-
castat together with the QTc interval prolongation observed in con-
scious telemetered Cynomolgusmonkeys can be considered as modest
with respect to the plasma concentrations found for these effects and
to those expected for beneﬁcial cardiovascular activity in humans.
These ﬁndings and the results of clinical trials in humans suggest that
etamicastat is not likely to prolong the QT interval at therapeutic doses.
Conﬂicts of interest
The authors report no relationships that could be construed as a
conﬂict of interest.
References
[1] Beliaev A, Learmonth DA, Soares-da-Silva P. Synthesis and biological evaluation of
novel, peripherally selective chromanyl imidazolethione-based inhibitors of dopa-
mine beta-hydroxylase. J Med Chem 2006;49:1191–7.
[2] BonifácioMJ, Igreja B,Wright L, Soares-da-Silva P. Kinetic studies on the inhibition of
dopamine-β-hydroxylase by BIA 5–453. PA2 Online 2009;7 [050P (abstract)].
[3] Hegde SS, Friday KF. Dopamine-beta-hydroxylase inhibition: a novel sympatho-
modulatory approach for the treatment of congestive heart failure. Curr Pharm
Des 1998;4:469–79.
[4] Ishii Y, Natsugoe K, Umezawa H. Pharmacological action of FD-008, a new
dopamine-beta-hydroxylase inhibitor. Arzneimittelforschung 1975;25:213–5.
[5] Kruse LI, Kaiser C, DeWolf JrWE, Frazee JS, Ross ST, Wawro J, et al. Multisubstrate in-
hibitors of dopamine beta-hydroxylase. 2. Structure–activity relationships at the
phenethylamine binding site. J Med Chem 1987;30:486–94.
[6] Ohlstein EH, Kruse LI, Ezekiel M, Sherman SS, Erickson R, DeWolf JrWE, et al. Cardio-
vascular effects of a new potent dopamine beta-hydroxylase inhibitor in spontane-
ously hypertensive rats. J Pharmacol Exp Ther 1987;241:554–9.
[7] Stanley WC, Lee K, Johnson LG, Whiting RL, Eglen RM, Hegde SS. Cardiovascular ef-
fects of nepicastat (RS-25560-197), a novel dopamine beta-hydroxylase inhibitor. J
Cardiovasc Pharmacol 1998;31:963–70.
[8] Sabbah HN, Stanley WC, Sharov VG, Mishima T, Tanimura M, Benedict CR, et al. Ef-
fects of dopamine beta-hydroxylase inhibition with nepicastat on the progression
of left ventricular dysfunction and remodeling in dogswith chronic heart failure. Cir-
culation 2000;102:1990–5.
[9] Gomes P, Soares-da-Silva P. Dopamine. In: BadenM, editor. Cardiovascular hormone
systems: from molecular mechanisms to novel therapeutics. Weinheim: Wiley-
VCH; 2008. p. 251–93.
[10] Jose PA, Eisner GM, Felder RA. Role of dopamine receptors in the kidney in the reg-
ulation of blood pressure. Curr Opin Nephrol Hypertens 2002;11:87–92.
[11] Jose PA, Soares-da-Silva P, Eisner GM, Felder RA. Dopamine and G protein-coupled
receptor kinase 4 in the kidney: role in blood pressure regulation. Biochim Biophys
Acta 1802;2010:1259–67.
[12] Soares-da-Silva P. Evidence for a non-precursor dopamine pool in noradrenergic
neurones of the dog mesenteric artery. Naunyn Schmiedebergs Arch Pharmacol
1986;333:219–23.
[13] Soares-da-Silva P. A comparison between the pattern of dopamine and noradrena-
line release from sympathetic neurones of the dog mesenteric artery. Br J Pharmacol
1987;90:91–8.
[14] Beliaev A, Ferreira H, Learmonth DA, Soares-da-Silva P. Dopamine β-
monooxygenase: mechanism, substrates and inhibitors. Curr Enzym Inhib 2009;5:
27–43.
[15] Kruse LI, DeWolf Jr WE, Chambers PA, Goodhart PJ. Design and kinetic characteriza-
tion of multisubstrate inhibitors of dopamine beta-hydroxylase. Biochemistry 1986;
25:7271–8.
24 M. Vaz-da-Silva et al. / IJC Metabolic & Endocrine 7 (2015) 10–24[16] Igreja B, Loureiro AI, Pires NM, Fernandes-Lopes C, Wright LC, Soares-da-Silva P.
Pharmacodynamic and pharmacokinetic proﬁle of dopamine-beta-hydroxylase in-
hibitor etamicastat in spontaneously hypertensive rats. Hypertension 2011;58:E68
[abstract].
[17] Igreja B, Pires NM, Wright L, Soares-da-Silva P. Effect of combined administration of
BIA 5–453 and captopril on blood pressure and heart rate. Hypertension 2008;52:
E62 [abstract].
[18] Igreja B, Pires NM, Wright LC, Soares-da-Silva P. Antihypertensive effects of a selec-
tive peripheral dopamine beta-hydroxylase inhibitor alone or in combination with
other antihypertensive drugs. Hypertension 2011;58:E161–2.
[19] Igreja B, Wright L, Soares-da-Silva P. Long-term lowering of blood pressure levels in
the SHR by selective peripheral inhibition of dopamine-b-hydroxylase with BIA
5–453. PA2 Online 2008;6 [087P (abstract)].
[20] Almeida L, Nunes T, Costa R, Rocha JF, Vaz-da-SilvaM, Soares-da-Silva P. Etamicastat,
a novel dopamine beta-hydroxylase inhibitor: tolerability, pharmacokinetics, and
pharmacodynamics in patients with hypertension. Clin Ther 2013;35:1983–96.
[21] Rocha JF, Vaz-da-Silva M, Nunes T, Igreja B, Loureiro AI, Bonifacio MJ, et al. Single-
dose tolerability, pharmacokinetics, and pharmacodynamics of etamicastat (BIA
5–453), a new dopamine {beta}-hydroxylase inhibitor, in healthy subjects. J Clin
Pharmacol 2012;52:156–70.
[22] Nunes T, Rocha JF, Vaz-da-Silva M, Igreja B, Wright LC, Falcao A, et al. Safety, tolera-
bility, and pharmacokinetics of etamicastat, a novel dopamine-beta-hydroxylase in-
hibitor, in a rising multiple-dose study in young healthy subjects. Drugs R D 2010;
10:225–42.
[23] Nunes T, Rocha JF, Vaz-da-SilvaM, Falcao A, Almeida L, Soares-da-Silva P. Pharmaco-
kinetics and tolerability of etamicastat following single and repeated administrationin elderly versus young healthy male subjects: an open-label, single-center, parallel-
group study. Clin Ther 2011;33:776–91.
[24] Nagatsu T, Udenfriend S. Photometric assay of dopamine-hydroxylase activity in
human blood. Clin Chem 1972;18:980–3.
[25] Verdoorn TA, Draguhn A, Ymer S, Seeburg PH, Sakmann B. Functional properties of
recombinant rat GABAA receptors depend upon subunit composition. Neuron
1990;4:919–28.
[26] Loureiro AI, Fernandes-Lopes C, Bonifacio MJ, Wright LC, Soares-da-Silva P. N-
acetylation of etamicastat, a reversible dopamine-beta-hydroxylase inhibitor. Drug
Metab Dispos 2013;41:2081–6.
[27] Zhou Z, Gong Q, Ye B, Fan Z, Makielski JC, Robertson GA, et al. Properties of HERG
channels stably expressed in HEK 293 cells studied at physiological temperature.
Biophys J 1998;74:230–41.
[28] Lu HR, Remeysen P, Somers K, Saels A, De Clerck F. Female gender is a risk factor for
drug-induced long QT and cardiac arrhythmias in an in vivo rabbit model. J
Cardiovasc Electrophysiol 2001;12:538–45.
[29] Trepanier-Boulay V, St-Michel C, Tremblay A, Fiset C. Gender-based differences in
cardiac repolarization in mouse ventricle. Circ Res 2001;89:437–44.
[30] Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, et al. Rela-
tionships between preclinical cardiac electrophysiology, clinical QT interval prolon-
gation and torsade de pointes for a broad range of drugs: evidence for a provisional
safety margin in drug development. Cardiovasc Res 2003;58:32–45.
[31] Pollard CE, Valentin JP, Hammond TG. Strategies to reduce the risk of drug-induced
QT interval prolongation: a pharmaceutical company perspective. Br J Pharmacol
2008;154:1538–43.
